Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
85 participants
INTERVENTIONAL
2017-01-31
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?
NCT02888041
Comparing Cervical Foley Catheter, Dinoprostone and a Combination of the Two for Labor Induction
NCT02815865
Cook Balloon Versus Propess After 12 Hours of Rupture of Membranes
NCT03310333
Artificial Induction of Labour in Full-term Singleton Pregnancy : Comparative Randomized Trial of Two Strategies
NCT04452747
Prostin and Propess in Induction of Labor
NCT01635439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When attending for induction of labor on delivery suite, an informed consent will be obtained then all women will have a cardiotocogram (CTG) performed initially and will be assessed by vaginal examination and Bishop score recorded at insertion of first slow-release pessary (Propess®10 mg Dinoprostone; CTS, UK), which will be inserted high into the posterior vaginal fornix. Assessment and insertion of pessary will be done by an experienced obstetrician or a senior midwife
All women will be given the required care and support as per the local protocols and guidelines
Women will be excluded from the study within the first 24 hours of induction of labor in the following conditions:
* Women with abnormal or non-reassuring CTG needing intervention.
* Women needing tocolytic use.
* Women needing removal of the Dinoprostone pessary.
* Women needing emergency Caesarean section.
* If spontaneous rupture of membranes occurs.
* If artificial rupture of membranes is achievable after the first 24 hours of induction of labor (Bishop score 5 or more)
* If woman withdraws her consent to continue as a part of the study.
After 24 hours from insertion of the first Dinoprostone pessary, women will be reassessed and a total of 330 women with Bishop score less than 7, will be randomly assigned to one of three intervention groups by a pre-formed computer-generated random list and randomization put in sealed opaque envelopes kept in a locked secure area on delivery suite.
Intervention groups will be as follows:
Group 1 (110 women):
Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required (Currently Propess® is not licensed to be repeated as a second dose. However, there is a consensus that, the dose may be repeated after a consultant review and an informed verbal consent as per SWH 00190 Induction and Augmentation of the First and Second Stage of Labour Management Guideline, 2012).
Group 2 (110 women):
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
Group 3 (110 women):
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
For all participants, after achieving spontaneous or artificial rupture of membranes, the local protocol for intrapartum care will be followed and after delivery, the women will be asked to fill in a patient's satisfaction questionnaire about the process of induction, care given and being a part of the study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Extension of propess+/-second propess
Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
10 mg Dinoprostone; CTS, UK
Prostin
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
3 mg Dinoprostone vaginal tablet; Pfizer, UK
Dilapan-S
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
Aquacryl hydrogel rod; HPSRx Enterprises, USA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
10 mg Dinoprostone; CTS, UK
3 mg Dinoprostone vaginal tablet; Pfizer, UK
Aquacryl hydrogel rod; HPSRx Enterprises, USA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Viable singleton pregnancy.
* Cephalic presentation.
* Intact membranes.
* No previous Caesarean section.
* No antenatal fetal concerns (Fetal growth restriction (FGR), small for gestational age (SGA), impaired Doppler, oligohydramnios, non-reassuring/abnormal CTG).
Exclusion Criteria
* Multiple pregnancy.
* Intrauterine fetal death.
* Non-cephalic presentation.
* Pre-labor rupture of membranes
* Previous one or more Caesarean sections.
* Antenatal concerns regarding fetal well-being (FGR, SGA, impaired Doppler, oligohydramnios, non-reassuring/abnormal CTG).
* Non-reassuring or abnormal CTG on admission to labor ward
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medicem International
UNKNOWN
Walsall Healthcare NHS Trust
OTHER
South Warwickshire NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Farag
Consultant Obstetrician and Gynaecologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amr H Farag, Consultant
Role: PRINCIPAL_INVESTIGATOR
Walsall Healthcare NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Walsall Healthcare NHS Trust
Walsall, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202984
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.